Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Umeclidinium (Incruse®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. |
|||
|
|||
Medicine details |
|||
| Medicine name | umeclidinium (Incruse®) | ||
| Formulation | 55 micrograms inhalation powder | ||
| Reference number | 1352 | ||
| Indication | Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease |
||
| Company | GlaxoSmithKline | ||
| BNF chapter | Respiratory system | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 3514 | ||
| NMG meeting date | 15/10/2014 | ||
| AWMSG meeting date | 12/11/2014 | ||
| Ratification by Welsh Government | 09/01/2015 | ||
| Date of issue | 13/01/2015 | ||
| Date of last review | 20/12/2017 | ||